Piper Sandler Remains a Hold on Blueprint Medicines (BPMC)
In a report released today, Allison Bratzel from Piper Sandler maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price target of $119.00. The company’s shares closed last Friday at $89.58.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
Bratzel covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Ultragenyx Pharmaceutical. According to TipRanks, Bratzel has an average return of 23.9% and a 59.26% success rate on recommended stocks.
In addition to Piper Sandler, Blueprint Medicines also received a Hold from Leerink Partners’s Andrew Berens in a report issued on March 3. However, today, Jefferies initiated coverage with a Buy rating on Blueprint Medicines (NASDAQ: BPMC).
The company has a one-year high of $121.90 and a one-year low of $80.68. Currently, Blueprint Medicines has an average volume of 953.1K.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Earlier this month, Ariel Hurley, the CAO of BPMC sold 1,326.00 shares for a total of $117,748.80.
Read More on BPMC:
Questions or Comments about the article? Write to editor@tipranks.com- Blueprint Medicines initiated with a Buy at Jefferies
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Blueprint Medicines initiated with an Outperform at Scotiabank
- Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit’s Liver Function Test Elevations
- Cautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth Projections
